A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Feb 21, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to track how well patients with liver cancer, specifically those related to the Hepatitis B virus, respond to radiotherapy. Researchers want to identify specific markers in the blood and tissues of patients that can help predict treatment outcomes. By analyzing samples collected before and after treatment, they aim to see how changes in these markers relate to the patient's response to therapy and any potential recurrence of the cancer.

To participate in this trial, individuals must be diagnosed with liver cancer and have a positive Hepatitis B surface antigen (HBsAg) test. They should have stable liver function and be planning to receive radiotherapy for their liver tumor. Patients will provide blood samples at various times during their treatment, which will help researchers learn more about the disease and how to improve future therapies. The findings from this study may lead to better monitoring of liver cancer treatments and more personalized care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with HCC by dynamic image criteria and/or biopsy
• • 2. HBsAg (+)
• • 3. Child-Turcotte-Pugh (CTP) class A-B liver function
• • 4. Radiotherapy to liver tumor as the main treatment
• Exclusion Criteria:
• • 1. Child-Turcotte-Pugh (CTP) class C liver functiECOG performance status score \>2
• • 2. Has had prior radiotherapy to the proposed treatment field.
• • 3. \< 18 years old